Breast Cancer Awareness Month brings attention to important advancements in cancer care, and today, we're partnering with ...
Not too long ago, pharmaceutical giant Astrazeneca reached a £200bn valuation—one of only a few London-listed FTSE 100 ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.
Sarepta will discontinue its next generation of exon-skipping drugs for Duchenne muscular dystrophy over safety concerns, in ...
Miller Value Partners portfolio manager John Spallanzani joined ‘Mornings with Maria’ to discuss the U.S. economy and stock market as oil prices fall to $78 a barrel. Sen. Shelley Moore Capito, R-W.
Pharmaceutical giant AstraZeneca said that the head of its China operations had been detained, after reports the firm was ...
Quotient Therapeutics, a company pioneering somatic genomics, today announced the appointment of Sir Mene Pangalos, Ph.D., to the company’s Board of Directors. Dr. Pangalos joins current board members ...
Chinese authorities detained AstraZeneca employees amid a probe into data privacy breaches and unlicensed drug sales, stock ...
The project partners tout California’s largest facility for converting landfill gas to renewable natural gas. Meanwhile, RNG ...
Weighing on London, AstraZeneca fell 8.2%, losing its top spot as the most valuable company on the FTSE 100 to oil major Shell in the process. The Cambridge-based pharmaceuticals firm fell back ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback